GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit

Chief Executive Officer Marc Hertz and Chief Scientific Officer Vipin Kumar to present on translating immune biology and clinical signals into novel therapeutic approaches for IPFLA JOLLA, CA, Sept. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. NASDAQ:GRI (“GRI Bio” or the “Company”), a biotechnology…